New study aims to predict immunotherapy success in cancer patients
NCT ID NCT07665697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will collect data from 500 cancer patients who are about to start immunotherapy. Researchers want to build a tool that can predict survival outcomes based on factors like combination treatments. The goal is to help doctors and patients make more informed decisions about using immunotherapy for malignant tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict which cancer patients will benefit from immunotherapy, leading to more personalized treatment plans.
- What could go wrong
- This is an observational study, not testing a new treatment. The prediction model may not be accurate for all patients or cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a simple text message transform cancer care?
- Can modern Radiotherapy's late effects be predicted?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva